Advertisement

Development of a dichloroacetic acid-hemoglobin conjugate as a potential targeted anti-cancer therapeutic

Authors

  • Ning Zhang,

    1. William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio
    Search for more papers by this author
  • Andre F. Palmer

    Corresponding author
    1. 231A Koffolt Laboratories, 140 West 19th Avenue, Columbus, Ohio 43210; telephone: +1-614-292-6033; fax: +1-614-292-3769
    • 231A Koffolt Laboratories, 140 West 19th Avenue, Columbus, Ohio 43210; telephone: +1-614-292-6033; fax: +1-614-292-3769.
    Search for more papers by this author

Abstract

This work focuses on conjugating the anti-cancer drug dichloroacetic acid (DCA) to the monocyte/macrophage targeting protein hemoglobin (Hb). The DCA–Hb conjugate carries approximately 12 DCA molecules per Hb tetramer, and binds to haptoglobin (Hp) forming stable DCA–Hb–Hp complexes, in a similar manner to unmodified Hb. The results of this study show that DCA–Hb–Hp is taken up by the monocytic cancer cell line THP-1, where it depolarizes the mitochondrial membrane potential, thereby inhibiting cancerous cell growth at a comparable level to free DCA. Taken together, the results of this study show promise for the use of the DCA–Hb conjugate as a potential therapeutic to treat monocytic leukemia. Biotechnol. Bioeng. 2011; 108:1413–1420. © 2011 Wiley Periodicals, Inc.

Ancillary